Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (Original): A combination comprising a benzo[g]quinoline derivative and/or a pharmaceutically acceptable salt thereof, and a prostaglandin derivative and/or a pharmaceutically acceptable salt thereof.

Claim 2. (Currently amended): [[A]] The combination of claim 1, wherein said benzo[g]quinoline is a compound of formula (I) and/or a pharmaceutically acceptable salt thereof



I

wherein

A and B are each H or form together an additional bond,

X is CH_2 or CO,

Y is O, S, NR_1 (R_1 being H or lower alkyl), CH_2 or O-CH_2, and

R is of formula (a), (b), (c), (d), (e), (f), (g), (h) or (i).


(a)


(b)


(c)


(d)


(e)


(f)


(g)


(h)


(i)

R_1 being H or lower alkyl,

R_2 being H, lower alkyl, or thienyl, e.g. 2-thienyl,

Z_1 being O or S,

Z_2 being CH or N,

in free base or acid addition salt form,

and wherein said prostaglandin derivative is a compound of formula (II) and/or a pharmaceutically acceptable salt thereof,



(II)

wherein G denotes OH, lower alkoxy, amino-lower-alkyl, ,
A and B are each H or form together an additional bond,
L is CO, $CHOR_1$ (R_1 being H or lower alkyl),
M is O, S, $(CH_2)_n$, (n being from 1 to 6),
Q is H or Ar, Ar being preferably phenyl which is unsubstituted or substituted one or more times by halogen, hydroxy, lower alkoxy, cyano, halo-lower-alkyl, e.g. trihalomethyl.

Claim 3. (Currently amended): The [[C]]combination of claim 1, wherein said benzo[g]quinoline is any compound selected from the group of:







R1 = H and CH3



R1 = H and CH3



and wherein said prostaglandin is any compound selected from the group of:



Latanoprost



Bimatoprost



Travoprost



Isopropyl Unoprostone



Ketolatanoprost

Claim 4. (Currently amended): [[A]] <u>The</u> combination of claim 1, wherein said benzo[g]quinoline is a compound of formula (I), and/or a pharmaceutically acceptable salt thereof, A and B are each H or form together an additional bond,



I

wherein

X is CH_2

Y is S, and

R is of formula (e), (f), or (h),



(e)



(f)



(h)

R_1 being H or lower alkyl,

Z_1 being S,

Z_2 being CH or N, and

R_2 being H, or lower alkyl.

Claim 5. (Currently amended): [[A]] The combination of claim 4, wherein the prostaglandin is selected from Latanoprost, Travaprost, Bimatoprost and Ketolatanoprost, preferably from Latanoprost and Travaprost, more preferably from Latanoprost.

Claim 6. (Currently amended): [[A]] The combination of claim 1 which comprises



& **Latanoprost**

Claim 7. (Currently amended): [[A]] The combination of claim 1 which comprises



& **Latanoprost**

Claim 8. (Currently amended): [[A]] The combination of claim 1 which comprises



& **Latanoprost**

Claim 9. (Cancelled)

Claim 10. (Currently amended): A [[M]]method to treat and or prevent glaucoma in a subject, which method comprises the administration of a medicament to said patient, which medicament comprises a benzo[g]quinoline derivative and a prostaglandin derivative.

Claim 11. (Currently amended): The [[M]]method of claim 5 wherein said subject is suffering from elevated levels of IOP.

Claim 12. (Currently amended): A [[M]]method of treating normal tension glaucoma (NTG), which method comprises the administration of a medicament to said patient, which medicament comprises a benzo[g]quinoline derivative and a prostaglandin derivative.

Claim 13. (Currently amended): The [[M]]method of claim 12, wherein the chorio-retinal and/or optic nerve blood flow of said patient is impaired.

Claim 14. (Currently amended): The [[M]]method of claim 10, wherein said administration is topical ocular administration.

Claim 15. (Currently amended): The [[C]]combination of claim 1, which is an ophthalmic composition.

Claim 16. (Currently amended): The [[C]]combination of claim 15, which is an ophthalmic insert.

Claim 17. (Currently amended): The [[C]]combination of claim 1 [[- 2,]] wherein the compounds of formula (I) and (II) are present in a ratio of from 50:1 up to 1:50.